199 related articles for article (PubMed ID: 10681344)
1. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.
Cushion MT; Collins M; Hazra B; Kaneshiro ES
Antimicrob Agents Chemother; 2000 Mar; 44(3):713-9. PubMed ID: 10681344
[TBL] [Abstract][Full Text] [Related]
2. Effects of atovaquone and diospyrin-based drugs on ubiquinone biosynthesis in Pneumocystis carinii organisms.
Kaneshiro ES; Sul D; Hazra B
Antimicrob Agents Chemother; 2000 Jan; 44(1):14-8. PubMed ID: 10602716
[TBL] [Abstract][Full Text] [Related]
3. Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.
Ittarat I; Asawamahasakda W; Bartlett MS; Smith JW; Meshnick SR
Antimicrob Agents Chemother; 1995 Feb; 39(2):325-8. PubMed ID: 7726490
[TBL] [Abstract][Full Text] [Related]
4. Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis?
Kaneshiro ES
Drug Resist Updat; 2001 Oct; 4(5):322-9. PubMed ID: 11991686
[TBL] [Abstract][Full Text] [Related]
5. Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone.
Basselin M; Hunt SM; Abdala-Valencia H; Kaneshiro ES
Eukaryot Cell; 2005 Aug; 4(8):1483-92. PubMed ID: 16087753
[TBL] [Abstract][Full Text] [Related]
6. Ubiquinone synthesis and its regulation in Pneumocystis carinii.
Kaneshiro ES; Basselin M; Merali S; Kayser O
J Eukaryot Microbiol; 2006; 53(6):435-44. PubMed ID: 17123407
[TBL] [Abstract][Full Text] [Related]
7. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure.
Walker DJ; Wakefield AE; Dohn MN; Miller RF; Baughman RP; Hossler PA; Bartlett MS; Smith JW; Kazanjian P; Meshnick SR
J Infect Dis; 1998 Dec; 178(6):1767-75. PubMed ID: 9815231
[TBL] [Abstract][Full Text] [Related]
8. Pneumocystis carinii synthesizes four ubiquinone homologs: inhibition by atovaquone and bupravaquone but not by stigmatellin.
Kaneshiro ES; Sul D; Basselin M; Kayser O
J Eukaryot Microbiol; 2001; Suppl():172S-173S. PubMed ID: 11906049
[No Abstract] [Full Text] [Related]
9. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS.
Kazanjian P; Armstrong W; Hossler PA; Lee CH; Huang L; Beard CB; Carter J; Crane L; Duchin J; Burman W; Richardson J; Meshnick SR
J Infect Dis; 2001 Mar; 183(5):819-22. PubMed ID: 11181161
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii.
Cirioni O; Giacometti A; Balducci M; Burzacchini F; Scalise G
J Antimicrob Chemother; 1995 Oct; 36(4):740-2. PubMed ID: 8591953
[No Abstract] [Full Text] [Related]
11. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.
Cirioni O; Giacometti A; Scalise G
J Antimicrob Chemother; 1997 Jan; 39(1):45-51. PubMed ID: 9044027
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis carinii pneumonia: the status of Pneumocystis biochemistry.
Kaneshiro ES
Int J Parasitol; 1998 Jan; 28(1):65-84. PubMed ID: 9504336
[TBL] [Abstract][Full Text] [Related]
13. Recapitulation in Saccharomyces cerevisiae of cytochrome b mutations conferring resistance to atovaquone in Pneumocystis jiroveci.
Hill P; Kessl J; Fisher N; Meshnick S; Trumpower BL; Meunier B
Antimicrob Agents Chemother; 2003 Sep; 47(9):2725-31. PubMed ID: 12936966
[TBL] [Abstract][Full Text] [Related]
14. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
Kovacs JA; Gill VJ; Meshnick S; Masur H
JAMA; 2001 Nov; 286(19):2450-60. PubMed ID: 11712941
[TBL] [Abstract][Full Text] [Related]
15. Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii.
Ball MD; Bartlett MS; Shaw M; Smith JW; Nasr M; Meshnick SR
Antimicrob Agents Chemother; 2001 May; 45(5):1473-9. PubMed ID: 11302813
[TBL] [Abstract][Full Text] [Related]
16. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
17. Composition of Pneumocystis carinii neutral lipids and identification of coenzyme Q10 as the major ubiquinone homolog.
Ellis JE; Wyder MA; Zhou L; Gupta A; Rudney H; Kaneshiro ES
J Eukaryot Microbiol; 1996; 43(3):165-70. PubMed ID: 8640186
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae.
Kessl JJ; Hill P; Lange BB; Meshnick SR; Meunier B; Trumpower BL
J Biol Chem; 2004 Jan; 279(4):2817-24. PubMed ID: 14576156
[TBL] [Abstract][Full Text] [Related]
19. Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
Contini C; Angelici E; Canipari R
J Antimicrob Chemother; 1999 Feb; 43(2):301-4. PubMed ID: 11252340
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of a rapid screening assay for identifying antipneumocystis agents.
Martinez A; Kovacs JA
Antimicrob Agents Chemother; 1993 Aug; 37(8):1674-8. PubMed ID: 8215282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
